Page 1770 - Hematology_ Basic Principles and Practice ( PDFDrive )

1574 Part IX Cell-Based Therapies

T lymphocytes targeting Epstein-Barr virus latent membrane proteins. 22. Morgan RA, Chinnasamy N, bate-Daga D, et al: Cancer regression
J Clin Oncol 32:798–808, 2014. and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
13. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing J Immunother 36:133–151, 2013.
data to identify mutated antigens recognized by adoptively transferred 23. Ramos CA, Savoldo B, Dotti G: CD19-CAR trials. Cancer J 20:112–118,
tumor-reactive T cells. Nat Med 19:747–752, 2013. 2014.
14. Rizvi NA, Hellmann MD, Snyder A, et al: Mutational landscape deter- 24. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al: T cells expressing
mines sensitivity to PD-1 blockade in non-small cell lung cancer. Science CD19 chimeric antigen receptors for acute lymphoblastic leukaemia
2015. in children and young adults: a phase 1 dose-escalation trial. Lancet
15. Morgan RA, Dudley ME, Wunderlich JR, et al: Cancer regression in 385:517–528, 2015.
patients after transfer of genetically engineered lymphocytes. Science 25. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-
314:126–129, 2006. Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malig-
16. Dotti G, Gottschalk S, Savoldo B, et al: Design and development of nancies Can Be Effectively Treated With Autologous T Cells Expressing
therapies using chimeric antigen receptor-expressing T cells. Immunol an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol 33:540–549,
Rev 257:107–126, 2014. 2015.
17. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in 26. Wang QS, Wang Y, Lv HY, et al: Treatment of CD33-directed chimeric
patients with metastatic synovial cell sarcoma and melanoma using antigen receptor-modified T cells in one patient with relapsed and refrac-
genetically engineered lymphocytes reactive with NY-ESO-1. J Clin tory acute myeloid leukemia. Mol Ther 23:184–191, 2015.
Oncol 29:917–924, 2011. 27. Gattinoni L, Lugli E, Ji Y, et al: A human memory T cell subset with
18. Arber C, Feng X, Abhyankar H, et al: Survivin-specific T cell receptor stem cell-like properties. Nat Med 17:1290–1297, 2011.
targets tumor but not T cells. J Clin Invest 125:157–168, 2015. 28. Xu Y, Zhang M, Ramos CA, et al: Closely related T-memory stem cells
19. Parkhurst MR, Yang JC, Langan RC, et al: T cells targeting carcinoem- correlate with in vivo expansion of CAR.CD19-T cells and are preserved
bryonic antigen can mediate regression of metastatic colorectal cancer by IL-7 and IL-15. Blood 123:3750–3759, 2014.
but induce severe transient colitis. Mol Ther 19:620–626, 2011. 29. Conlon KC, Lugli E, Welles HC, et al: Redistribution, hyperprolifera-
20. Bendle GM, Linnemann C, Hooijkaas AI, et al: Lethal graft-versus- tion, activation of natural killer cells and CD8 T cells, and cytokine
host disease in mouse models of T cell receptor gene therapy. Nat Med production during first-in-human clinical trial of recombinant human
16:565–570, 1p, 2010. interleukin-15 in patients with cancer. J Clin Oncol 33:74–82, 2015.
21. Linette GP, Stadtmauer EA, Maus MV, et al: Cardiovascular toxicity 30. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune
and titin cross-reactivity of affinity-enhanced T cells in myeloma and correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454,
melanoma. Blood 122:863–871, 2013. 2012.